HeartBeam Appoints Alan Baumel As Chief Operating Officer
Commercial Medical Device Veteran to Lead Rollout of HeartBeam Platform Technology
HeartBeam, Inc. , a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, has appointed Alan Baumel as Chief Operating Officer.
Recommended AI News : Traverse Systems Partners with mdf commerce’s InterTrade to Expand Offerings
For over 35 years, Mr. Baumel has built a reputation as a highly experienced product development, manufacturing, quality assurance, and regulatory affairs professional. He has a strong record of ensuring efficient and successful product commercial approvals and launches at small and large organizations. Before joining HeartBeam, Mr. Baumel was Program Director of the Case for Quality Collaborative Community at Medical Device Innovation Consortium, where he elevated the focus of all medical device stakeholders from baseline quality and regulatory compliance to sustained, predictive practices that advance medical device quality and safety to achieve better patient outcomes. Previously he was Senior Vice President overseeing Product Development, Manufacturing, Quality Assurance, and Regulatory Affairs at Bardy Diagnostics (acquired by Hillrom), a medical device venture that developed the first and only P-wave centric ambulatory ECG monitor. He has also served with multiple medical device companies, including W. L. Gore & Associates, Ablation Frontiers (acquired by Medtronic), and Cameron Health (acquired by Boston Scientific).
As Chief Operating Officer, which is a new role at HeartBeam, Mr. Baumel will lead product development, manufacturing, quality assurance, and regulatory affairs.
“On behalf of our board and management team, we are privileged to be welcoming Alan to our Company, bringing over three decades of leadership in the medical device industry working to deliver products to market,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “His extensive experience and industry knowledge will be instrumental in accelerating our commercialization path and FDA product development. Alan’s deep experience, particularly with cardiac devices, is an ideal fit for our heart attack detection and monitoring technology solutions. Alan will not only solidify our core management team but also prepare the Company to commercialize and scale our technology.”
Mr. Baumel added, “Being part of an innovative company that is positioning itself to capture a large share of the MI detection market is a perfect fit for me. My immediate goals will be to enhance and streamline HeartBeam’s telehealth and ER software product development and regulatory plan, improve overall operations and move the Company toward its FDA studies and submissions and subsequent product launches. I look forward to working with Branislav and the team and leveraging my experience and clinical relationships to drive HeartBeam’s commercialization success.”
Recommended AI News:
[To share your insights with us, please write to